Apalutamide in nmCRPC: QOL as Good as ADT Alone

ARTICLES

Apalutamide in nmCRPC: QOL as Good as ADT Alone

MEDSCAPE
PUBLISHED: 27 MARCH 2018

New results suggest that health-related quality of life (HRQOL) is good with the new-generation antiandrogen inhibitor apalutamide (Erleada, Janssen), which recently became the first agent to be approved for use in men with nonmetastatic castrate-resistant prostate cancer (nmCRPC).